GC launched the Mogam Institute for Biomedical Research, its
nonprofit research wing, in 1984 with the proceeds it earned
from Hepavax, the company’s hepatitis-B vaccine (the third
successful one in the country).
The institute is tasked with promoting advances in biomedical
technology, reinvesting its profits in fostering a stable and
conducive environment for research. It is also the first-ever
nonprofit research corporation established with the Ministry of
Science and Technology (currently the Ministry of Science and
ICT) in Korea.
We are conducting research to develop new drugs using artificial
intelligence.